1. Home
  2. DTF vs DBVT Comparison

DTF vs DBVT Comparison

Compare DTF & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo DTF Tax-Free Income 2028 Term Fund Inc.

DTF

DTF Tax-Free Income 2028 Term Fund Inc.

N/A

Current Price

$11.39

Market Cap

79.8M

Sector

Finance

ML Signal

N/A

DBVT

DBV Technologies S.A.

HOLD

Current Price

$18.40

Market Cap

508.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DTF
DBVT
Founded
1991
2002
Country
United States
France
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
79.8M
508.8M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
DTF
DBVT
Price
$11.39
$18.40
Analyst Decision
Buy
Analyst Count
0
6
Target Price
N/A
$19.04
AVG Volume (30 Days)
21.1K
452.4K
Earning Date
01-01-0001
10-28-2025
Dividend Yield
3.64%
N/A
EPS Growth
N/A
N/A
EPS
0.44
N/A
Revenue
N/A
$5,502,000.00
Revenue This Year
N/A
$1,768.71
Revenue Next Year
N/A
$1,028.88
P/E Ratio
$24.34
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.29
$2.74
52 Week High
$11.19
$21.50

Technical Indicators

Market Signals
Indicator
DTF
DBVT
Relative Strength Index (RSI) 52.33 71.05
Support Level $11.33 $12.75
Resistance Level $11.44 $21.50
Average True Range (ATR) 0.06 1.17
MACD 0.01 0.70
Stochastic Oscillator 52.97 68.34

Price Performance

Historical Comparison
DTF
DBVT

About DTF DTF Tax-Free Income 2028 Term Fund Inc.

DTF Tax-Free Income 2028 Term Fund Inc is a diversified closed-end management investment company. The Fund's investment objective is current income exempt from regular federal income tax consistent with the preservation of capital. It seeks to achieve its investment objective by investing primarily in a diversified portfolio of investment-grade tax-exempt obligations.

About DBVT DBV Technologies S.A.

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.

Share on Social Networks: